Matthias Courvoisier

Matthias has extensive experience in public and private capital market transactions, including initial public offerings, capital increases, rights offerings, accelerated bookbuildings, convertible bonds, straight bonds and liability management transactions. He regularly advises on public takeover offers, take-private transactions, de-listings and complex corporate reorganisations. In addition, he represents clients in public and private M&A transactions across a variety of industries, including life sciences, technology, industrials, financial services and real estate.

Matthias is consistently ranked Band 1 for Capital Markets by Chambers and recognised as a Leading Partner by The Legal 500. Clients praise his commercial judgement, technical excellence, innovative thinking and pragmatic approach. He is a recognised thought leader in Swiss capital markets law, co-editor of a leading commentary on the Listing Rules of SIX Swiss Exchange, a member of the Editorial Board of CapLaw, and a frequent speaker on capital markets, public M&A and corporate governance matters. He served as a member of the committee entrusted with drafting the standards for auditing public takeover offers and participated in the development of the SIX Swiss Exchange rules governing the listing of SPACs.

He graduated from the University of Zurich, obtained a doctorate in law with the highest distinction (summa cum laude), and earned a Master in Finance from London Business School with distinction. He was admitted to the Swiss Bar in 2000.

DEALS LIST

Public Markets Transactions

• 2025/2026: Advised SIX listed HT5 AG (former Hochdorf Holding AG) in restructuring its CHF 125 million perpetual bond, in getting out of composition proceedings after that restructuring, in merging with Centiel SA, in the secondary placement of shares to new investors, and the listing under its new name Centiel SA.*
• 2025/2026: Advised funds invested into the convertible bonds of Meyer Burger in their efforts to restructure and/or sell Meyer Burger or their technology.*
• 2017 through 2026: Advised Highbridge Capital Management in financing Santhera Pharmaceuticals Holding AG.*
• 2025: Advised DocMorris in its CHF 45 million senior unsecured convertible bond placement, guaranteed by DocMorris, and the related buyback of the outstanding CHF 87.6 million convertible bonds due in September 2026.*
• 2025: Advised SIX-listed DocMorris on its CHF 208 million rights offering (2025), its various convertible bonds (including share lending facility and concurrent delta placement), its accelerated bookbuildings (ABBs), its straight bonds and its other liability management transactions (including repurchase offers).*
• 2024: Advised Georg Fischer AG on all Swiss aspects of its acquisition of Uponor Oy.*
• 2023: Advised VT5 AG in its De-Spac transaction and acquisition of R&S Group.*
• 2023: Advised Cicor Technologies AG in the mandatory takeover bid of OEP 80 B.V.*
• 2023: Advised the major shareholders of Athris AG in the taking private of listed Athris AG.*
• 2023: Advised Schaffner Holding AG in the takeover bid by TE Connectivity Ltd.*
• 2022: Advised Cicor Technologies Ltd. in the issue of its 2027 0% mandatory convertible bond, listed at SIX Swiss Exchange.*
• 2022: Acted for the issuer, underwriters or depositary bank in each of the four inaugural global depositary receipts (GDR) listings on SIX Swiss Exchange under China-Switzerland Stock Connect, consisting of the offerings by Gem Co., Gotion High-tech Co., Keda Industrial Group Co. and Ningbo Shanshan Co. with total proceeds of over USD 1.5 billion.*
• 2021/2022: Advised Cosmo Pharmaceuticals in its taking private of Cassiopea S.p.A. in a share exchange offer.*
• 2021: Structured the first Special Purpose Acquisition Company (SPAC) under Swiss law and advised VT5 Acquisition Company, the first Swiss-listed SPAC, on its initial public offering.*
• 2017: Advised Cosmo Pharmaceuticals on its private placement of shares worth CHF 216 million.*
• 2016: Advised Arbonia AG on its CHF 415 million public takeover of Looser Holding AG.*
• 2016: Acted as transaction counsel in the IPO for Varia US Properties AG.*
• 2016: Advised Cosmo Pharmaceuticals on its move to the Netherlands.*
• 2020: Advised Zur Rose Group on its first convertible bond offering.*
• 2020: Advised Implantica AG on its cross-border IPO.*
• 2018: Acted as Swiss banks counsel for UBS and Joh. Berenberg, Gossler & Co. KG in the IPO of Zur Rose Group AG.*

Private Markets Transactions

• 2026: Advised TTM Technologies, Inc. on its acquisition of Swiss Technology Group AG from its former owner Afinum.*
• 2025: Advised the owner of multi hundred million business in its sale of part of the business to private equity investor.*
• 2025: Advised SIX-listed Arbonia AG on the sale of its climate division to Midea Group for EUR 742 million.*
• 2024: Advised Numab Therapeutics AG in the sale of its NM26 business by a tax neutral spin-off and subsequent sale of the spun-out newly formed subsidiary, Yellow Yersey Therapeutics AG, to J&J.*
• 2024: Advised Numab Therapeutics AG in relation to closing a CHF 50 million (approximately USD 55 million) Series C top-up financing round.*
• 2024: Advised SIX-listed R&S Group Holding AG in the acquisition of Kyte Powertech, an Irish transformer manufacturer, and its financing through equity commitments and a CHF 233 bridge loan.*
• 2024: Advised Georg Fischer on the acquisition of the VAG Group from Aurelius.*
• 2023: Advised DocMorris AG on its sale of its Swiss business to Migros.*

*Matter handled prior to joining Pestalozzi